E
eTheRNA immunotherapies
Messenger RNA immunotherapies for cancer and infectious diseases
About eTheRNA immunotherapies
Ethernabe is a seasoned player in the RNA technology industry, boasting over three decades of experience. The company primarily serves pharmaceutical and biotech companies, both emerging and established, that have an interest in RNA therapeutics. Ethernabe's business model revolves around providing professional partnership and support for start-up, early stage, and late stage projects. They do this by leveraging their proprietary platforms in RNA chemistry, LNP formulation, and Process Technology.
Read full description
The company's proprietary platforms are designed to help drive new pipeline development or resolve manufacturing challenges for their partners. They have developed innovative LNP platforms tailored for specific routes of administration such as intravenous (IV), intra-tumoral (IT), and intramuscular (IM), which allows for better targeted biodistribution. This means that the medicine can be delivered more accurately to the target tissue.
Ethernabe's proprietary mRNA chemistry platform technology allows for sequence engineering of mRNA constructs. This ensures optimal mRNA translation efficiency and maximal mRNA stability. The sequence engineering can be adjusted to enable immune silent or immune-stimulatory mRNA. Additionally, constructs can be optimized for improved tissue specific expression.
Ethernabe's revenue is generated through their partnerships with pharma and biotech companies, as well as through the continuation of their pipeline products. These include IV administered HPC16+ cancer treatment and an intra-tumoral platform containing a proprietary immune-activating mix.
The company also has a cGMP accredited RNA production facility in Niel, Belgium, where they have over 5 years of GMP RNA production experience and more than 30 years of manufacturing research grade RNA.
At a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Antwerp, Belgium
- Employees
- 91
- Open positions
- None listed
- Dealroom signal
- 31.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Genetics and genomics, Patient Care, Immune System, Spinout, Biotech and Pharma, mRNA Medicines, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2026 | $0 | — | Valerio Therapeutics | ↗ |
| SERIES BOther financing | Aug 2022 | $43M | $172M | PMV · FundPlus · Kenneth Chien · Novalis Lifesciences | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for eTheRNA immunotherapies is 4.3K monthly website visits, down 18.9% over the last three months. eTheRNA immunotherapies's team declined 1.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
IWT
The Institute for the Promotion of Innovation by Science and Technology in Flanders
European Commission
Series A11 investors entered at this stage
EQT Life Sciences
PMV
MVM Life Science Partners
Omega Funds
BNP Paribas Fortis
Boehringer Ingelheim Venture Fund
FundPlus
Novalis Lifesciences
Yijing Capital
Kenneth Chien
China Grand Pharmaceutical and Healthcare Holdings
Other known investors2 additional known investors
Valerio Therapeutics
Vrije Universiteit Brussel
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about eTheRNA immunotherapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See eTheRNA immunotherapies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.